Dare Bioscience Inc (DARE): Next-Year EPS Estimate 30.77%
As of 2026-11-06, Dare Bioscience Inc (DARE) has a next-year EPS growth estimate of 30.77%. Featured in 2 EPS revision reports, most recently on 2026-04-20.
On 2026-10-30, analyst consensus for DARE's next-year EPS growth shifted from 35.43% to 30.77% — a negative change of 4.66 percentage points. The revised estimate has been sustained across 7 subsequent trading sessions. Current-year growth is projected at 38.61%.
What's Driving This
The provided EPS revision
Generated 2026-11-02 from news as of 2026-11-02
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 30.77%
- EPS growth this year
- 38.61%
- EPS next quarter (est)
- -$0.13
- Last price
- $0.62
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-11-06 | 30.77% | 38.61% | -$0.13 | $0.62 |
| 2026-11-05 | 30.77% | 38.61% | -$0.13 | $0.62 |
| 2026-11-04 | 30.77% | 38.61% | -$0.13 | $0.66 |
| 2026-11-03 | 30.77% | 38.61% | -$0.13 | $0.65 |
| 2026-11-02 | 30.77% | 38.61% | -$0.13 | $0.65 |
| 2026-10-31 | 30.77% | 38.61% | -$0.13 | $0.70 |
| 2026-10-30 | 30.77% | 38.61% | -$0.13 | $0.70 |
| 2026-10-29 | 35.43% | 33.75% | -$0.16 | $0.68 |
| 2026-10-28 | 35.43% | 33.75% | -$0.16 | $0.68 |
| 2026-10-27 | 35.43% | 33.75% | -$0.16 | $0.66 |
| 2026-10-26 | 35.43% | 33.75% | -$0.16 | $0.64 |
| 2026-10-23 | 47.02% | 34.72% | -$0.14 | $0.65 |
| 2026-10-22 | 47.02% | 34.72% | -$0.14 | $0.65 |
| 2026-10-21 | 47.02% | 34.72% | -$0.14 | $0.69 |
| 2026-10-20 | 47.02% | 34.72% | -$0.14 | $0.69 |
| 2026-10-19 | 47.02% | 34.72% | -$0.14 | $0.71 |
| 2026-10-16 | 47.02% | 34.72% | -$0.14 | $0.72 |
| 2026-10-15 | 47.02% | 34.72% | -$0.14 | $0.74 |
| 2026-10-14 | 47.02% | 34.72% | -$0.14 | $0.73 |
| 2026-10-13 | 47.02% | 34.72% | -$0.14 | $0.75 |
| 2026-10-12 | 47.02% | 34.72% | -$0.14 | $0.75 |
| 2026-10-11 | 47.02% | 34.72% | -$0.14 | $0.77 |
| 2026-10-10 | 47.02% | 34.72% | -$0.14 | $0.77 |
| 2026-10-09 | 47.02% | 34.72% | -$0.14 | $0.77 |
| 2026-10-08 | 47.02% | 34.72% | -$0.14 | $0.77 |
| 2026-10-07 | 47.02% | 34.72% | -$0.14 | $0.79 |
| 2026-10-06 | 47.02% | 34.72% | -$0.14 | $0.83 |
| 2026-10-05 | 47.02% | 34.72% | -$0.14 | $0.84 |
| 2026-10-04 | 47.02% | 34.72% | -$0.14 | $0.84 |
| 2026-10-03 | 47.02% | 34.72% | -$0.14 | $0.84 |
Reports Featuring DARE
Recent News
- Dare Bioscience Announces Pricing of $6.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesGlobeNewswire
- Dare Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved TherapiesGlobeNewswire
- Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ...GuruFocus.com
- Dare Bioscience Reports Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Dare Bioscience Inc (DARE) Q4 2025 Earnings Report Preview: What To ExpectGuruFocus.com
Screen Performance
Aggregate stats across all 2130 tickers our top-EPS-revision screen has flagged over the past 219 days.
- Median return since detection
- -3.9%
- % of tickers in the green
- 41%
- Median return on winners
- +23.3%
- Large revisions captured
- 2083
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Dare Bioscience Inc's next-year EPS growth estimate?▾
As of 2026-11-06, Dare Bioscience Inc (DARE) has a next-year EPS growth estimate of 30.77%, based on analyst consensus.
When was the latest EPS estimate revision for DARE?▾
The most recent revision occurred on 2026-10-30, when analysts adjusted the next-year EPS growth estimate from 35.43% to 30.77%.
What sector and industry does Dare Bioscience Inc belong to?▾
Dare Bioscience Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. DARE appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Dare Bioscience Inc (DARE) appears here because it was detected by our daily top-EPS-revision-performer screen.